Caliway Biopharmaceuticals Co. L
6919
Classement en actions
#4346
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Prix de l'action
$2.29
Capitalisation boursière
$3.56B
Changement (1 jour)
-2.50%
Changement (1 an)
-57.22%
Pays
TW
Échange Caliway Biopharmaceuticals Co. L (6919)
Catégorie
Healthcare
Historique du rendement du dividende pour Caliway Biopharmaceuticals Co. L (6919)
Le rendement du dividende (TTM) de Caliway Biopharmaceuticals Co. L (symbole boursier : 6919) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Caliway Biopharmaceuticals Co. L (6919) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
| Année | Rendement du dividende | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
| Entreprise | Rendement du dividende | Pays |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
